CRVO — CervoMed Inc.
NASDAQ · Healthcare · Biotechnology
$2.59
+$0.02 (+0.78%)
CervoMed Inc. (CRVO) is a biotechnology company listed on NASDAQ. It is led by John J. Alam M.D., based in 20 Park Plaza, Boston, MA, United States, 02116, with about 15 employees. CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Latest reported CRVO revenue for 2025-09-30 was $322.6K. Net income was -$7.7M. Revenue was down 81.6% from 2025-06-30 to 2025-09-30. CRVO currently screens at market cap $28.8M.
Use this CRVO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRVO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRVO SEC filings page. Lician reads the product cache first so this HTML stays unique to CervoMed Inc. even when a live quote feed is slow.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CRVO Key Statistics
Market Cap
$28.79M
Volume
219,958
Previous Close
$2.63
Day Range
$2.60 – $2.73
EPS
$0.00
Revenue
$9.74M
Net Income
-$16.29M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+36.3%
Profit Margin
-167.3%
Employees
15
CRVO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.74M | $7.14M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$16.29M | -$2.17M | -$5.80M | -$24.10M |
| EPS (Diluted) | $0.00 | $0.00 | $2.04M | $1.95M |
Total Assets
$43.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$9.00M
Operating Cash Flow
-$16.53M
Free Cash Flow
$0.00
CervoMed Inc. Company Information
- Co-Founder, CEO, President & Director
- John J. Alam M.D.
- Headquarters
- 20 Park Plaza, Boston, MA, United States, 02116
- Website
- www.cervomed.com
- Phone
- 617 744 4400
- IPO / Founded
- 2016-01-04
- Sector
- Healthcare
- Industry
- Biotechnology